Compare ORGN & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORGN | ADAG |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | China |
| Employees | 91 | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 254.4M |
| IPO Year | N/A | 2020 |
| Metric | ORGN | ADAG |
|---|---|---|
| Price | $1.12 | $3.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 140.7K | ★ 186.8K |
| Earning Date | 05-14-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $503.74 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $1.44 |
| 52 Week High | $4.11 | $4.75 |
| Indicator | ORGN | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 31.96 | 52.01 |
| Support Level | $0.15 | $3.29 |
| Resistance Level | $2.33 | $4.09 |
| Average True Range (ATR) | 0.09 | 0.31 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 13.00 | 43.33 |
Origin Materials Inc is a technology company with a mission to enable the world's transition to sustainable materials. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include PET circular caps and closures, Para-xylene, carbon black, Levulinic acid, among others, by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.